Key Consolidated Financial Results (Q1 FY27 vs Q1 FY26)

  • Revenue From Operations: ₹178.7 crore (vs ₹33.4 crore) - 435% increase
  • Total Revenue: ₹182.4 crore (vs ₹34.6 crore) - 427% increase
  • Gross Profit: ₹76.2 crore (vs ₹12.7 crore) - 500% increase
  • Gross Profit Margin: 41.8% (vs 36.7%) - 510 bps improvement
  • EBITDA: ₹27.3 crore (vs ₹5.9 crore) - 363% increase
  • EBITDA Margin: 14.9% (vs 17.1%) - 220 bps decrease
  • PAT: ₹7.9 crore (vs ₹1.4 crore) - 464% increase
  • PAT Margin: 4.3% (vs 4.1%) - 20 bps improvement

Note: Consolidated figures for Q1FY27 include a full quarter of Noumed Pharmaceuticals (consolidated from November 12, 2025), making year-on-year comparisons not like-for-like.

Key Standalone Financial Results (Q1 FY27 vs Q1 FY26)

  • Revenue From Operations: ₹52.8 crore (vs ₹19.2 crore) - 174.9% increase
  • Total Revenue: ₹56.2 crore (vs ₹20.4 crore) - 174.8% increase
  • Gross Profit: ₹22.1 crore (vs ₹9.8 crore) - 126.5% increase
  • Gross Profit Margin: 39.3% (vs 47.7%) - 840 bps decrease
  • EBITDA: ₹16.8 crore (vs ₹4.3 crore) - 292.7% increase
  • EBITDA Margin: 29.8% (vs 20.9%) - 890 bps improvement
  • PAT: ₹8.9 crore (vs ₹0.8 crore) - 975.1% increase
  • PAT Margin: 15.8% (vs 4.0%) - 1180 bps improvement

Strategic Business Developments

Proposed Variation in IPO Proceeds Utilization

The Board of Directors has approved a proposed variation in the objects of the issue, subject to shareholder approval:

  • Redeploying ₹83.83 crore originally earmarked for capacity expansion and upgradation of manufacturing facilities
  • Redeploying ₹18.02 crore originally earmarked for a new research and development centre
  • Total redeployment: ₹101.85 crore towards majority stakes in two operating pharmaceutical assets
  • The purpose remains unchanged (EU-GMP compliant injectable capacity and dedicated R&D platform), only execution method varies

Acquisition of 60% Stake in Saicriti Pharma Private Limited

  • Investment of ₹83.83 crore for 60% equity stake in newly established Saicriti Pharma Private Limited
  • Saicriti is constructing a critical-care injectable facility at Gummadidala (outside Outer Ring Road) on 15,000+ square yard site
  • Facility being built to EU-GMP and USFDA standards with complex injectables, lyophilisation and GLP-compliant laboratories
  • Total project cost: ₹215 crore
  • Promoters of Saicriti funding 40% equity (₹55.89 crore)
  • Project debt: ₹75.24 crore with 3-year moratorium and 7-year repayment schedule
  • No premium paid - entire ₹83.83 crore applied toward facility construction
  • Expected capacity: 154.66 million units (vs original plan of 105 million units) - 47% increase
  • Expected completion: April 2027 (extended by one month from original plan)

Acquisition of 60% Stake in Prathyak Laboratories Private Limited

  • SP Analytics Private Limited (R&D subsidiary) to acquire 60% stake for ₹18.02 crore
  • Prathyak operates established R&D centre at Genome Valley, Hyderabad with 3 years operating history
  • 65 personnel including 28 research scientists
  • Pipeline of 150 SKUs across 86 molecules
  • Capabilities in lyophilised, liposomal and nano-based complex injectables and oncology
  • Expected completion date: on or before September 30, 2026
  • Will become step-down subsidiary

Australian Operations Update

  • AUD 53 million facility funding completed
  • Company contributing AUD 3.5 million through Singapore subsidiary (AUD 1.75 million already infused, balance AUD 1.75 million approved)
  • Australian shareholders contributed AUD 1.5 million
  • Construction on schedule:
  • Physical completion: January 2027
  • TGA licensing inspection: March 31, 2027
  • Phase 1 manufacturing: April 2027

US Market Entry Preparation

  • Board approved incorporation of US subsidiary
  • To be held as step-down subsidiary through Sai Parenterals Pte. Limited, Singapore
  • Expected incorporation within next ten days
  • Evaluation at preliminary stage

Management Commentary

Mr. Anil Kumar Karusala, Chairman and Managing Director, provided the following insights:

  • Q1 revenue represents approximately 24% of FY27 ₹750 crore revenue target
  • Gross margin improved to 41.8% from 38.1% in Q4FY26 due to negotiated price revisions
  • Contracts have 90-120 day window for price revision implementation
  • Elevated air-freight costs in Australia due to industry-wide shipping disruption affected margins
  • West Asia situation delayed consignments, forcing air shipments
  • Reiterated FY27 guidance: ₹750 crore revenue with ~17% EBITDA margin
  • Second half weighting expected as per historical business pattern

Company Background

Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise with:

  • 302 commercial products across nine therapeutic areas
  • 599 approved registrations
  • 67 dossiers under development
  • Six manufacturing facilities (five in India, one in Australia)
  • GMP, WHO-GMP, TGA-Australia and PIC/S accreditations
  • Through Noumed Pharmaceuticals: 15 exclusive long-term supply agreements covering 526 SKUs
  • Over 451 TGA-approved dossiers
  • More than 50% of consolidated revenue under long-term regulated-market agreements
  • Completed IPO in March 2026, listed on BSE/NSE on April 02, 2026